Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. · 2023

Read Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. by Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10504075.txt.

Description

Lesokhin led the MagnetisMM-3 trial in 2023 on a new antibody drug for a blood cancer that had come back. The cancer is multiple myeloma, which grows in the bone marrow. The drug, elranatamab, links two targets: BCMA on cancer cells and CD3 on immune T cells. That link drags T cells onto the cancer to kill it.

Cohort A held 123 patients with no prior BCMA-targeted care. Lesokhin reports a response rate of 61.0%, with 35.0% in full response. Half of the responders later switched to doses every two weeks. Most of them kept or deepened their response for six months or more. Infections were the most common side effect, at 69.9%.

Catalog record

CREATORLesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE59 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10504075

Browse the full library · About the Tower of Babel